NOS2 and breast cancer: Constitutive iNOS expression abolished clonogenicity in ZR-75-1 breast cancer cells13 and sensitized to cisplatin in human cancer cell lines and murine RIF-1 xenografts9 and in A549 models of human primary and metastatic lung cancer.17